US FDA Approves Oral Drug 'Gavreto' to Treat Lung Cancers
The lung cancer drug, Gavreto, on September 5 has passed the approval standards of the US Food and Drug Administration (USFDA). The drug, developed by Roche Holding AG in collaboration with Blueprint Medicines Corp, is intended to treat patients with Non-Small Cell Lung Cancer (NSCLC). Gavreto is an oral RET-targeted therapy. Reportedly, it is designed to selectively inhibit RET alterations that cause many types of cancer including NSCLC.